Teva receives FDA approval for generic TOBI

As part of its agreement with Novartis on this product, Teva expects to launch this product in late November.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that the US Food and Drug Administration (FDA) has granted approval of its generic equivalent to TOBI (Tobramycin Inhalation Solution USP). TOBI, marketed by Novartis, is an inhaled antibiotic for the treatment of cystic fibrosis with annual sales of $350 million in the US, according to IMS data as of June 30, 2013.

As part of its agreement with Novartis on this product, Teva expects to launch this product in late November.

Published by Globes [online], Israel business news - www.globes-online.com - on October 14, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018